Although insulin-like growth factor 1 (IGF-1) has been associated with retinopathy, proof of a direct relationship has been lacking. Here we show that an IGF-1 receptor antagonist suppresses retinal neovascularization in vivo, and infer that interactions between IGF-1 and the IGF-1 receptor are necessary for induction of maximal neovascularization by vascular endothelial growth factor (VEGF). IGF-1 receptor regulation of VEGF action is mediated at least in part through control of VEGF activation of p44/42 mitogen-activated protein kinase, establishing a hierarchical relationship between IGF-1 and VEGF receptors. These findings establish an essential role for IGF-1 in angiogenesis and demonstrate a new target for control of retinopathy. They also explain why diabetic retinopathy initially increases with the onset of insulin treatment. IGF-1 levels, low in untreated diabetes, rise with insulin therapy, permitting VEGF-induced retinopathy.
Early treatment diabetic retinopathy study research group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98, 766–785 (1991).
Zimmer-Galler, I.E., Bressler, N.M. & Bressler, S.B. Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Int. Ophthalmol. Clin. 35, 37–57 (1995).
Pierce, E.A., Foley, E.D. & Smith, L.E. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 114, 1219–1228 (1996); erratum: 115, 427 (1997).
Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738–4747 (1995).
Stone, J. et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 37, 290–299 (1996).
Pierce, E.A., Avery, R.L., Foley, E.D., Aiello, L.P. & Smith, L.E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA 92, 905–909 (1995).
Boulton, M., Foreman, D., Williams, G. & McLeod, D. VEGF localisation in diabetic retinopathy. Br. J. Ophthalmol. 82, 561–568 (1998).
Robinson, G.S. et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. USA 93, 4851–4856 (1996).
Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457–10461 (1995).
Borgstrom, P., Bourdon, M.A., Hillan, K.J., Sriramarao, P. & Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35, 1–10 (1998).
Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 4, 336–340 (1998).
Smith, L.E. et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706–1709 (1997).
Sharp, P.S. et al. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30, 199–207 (1987).
Merimee, T.J., Fineberg, S.E., McKusick, V.A. & Hall, J. Diabetes mellitus and sexual ateliotic dwarfism: a comparative study. J. Clin. Invest. 49, 1096–1102 (1970).
Wright, A.D. et al. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. Br. Med. J. 2, 346–348 (1969).
Sonksen, P.H., Russell-Jones, D. & Jones, R.H. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm. Res. 40, 68–79 (1993).
Merimee, T.J., Zapf, J. & Froesch, E.R. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N. Engl. J. Med. 309, 527–530 (1983).
Amiel, S.A. et al. Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 33, 1175–1179 (1984).
Grant, M., Russell, B., Fitzgerald, C. & Merimee, T.J. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 35, 416–420 (1986).
Pfeiffer, A., Spranger, J., Meyer-Schwickerath, R. & Schatz, H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes 46, S26–30 (1997).
Meyer-Schwickerath, R. et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 92, 2620–2625 (1993).
Hyer, S.L., Sharp, P.S., Brooks, R.A., Burrin, J.M. & Kohner, E.M. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 38, 586–589 (1989).
Dills, D.G., Moss, S.E., Klein, R., Klein, B.E. & Davis, M. Is insulinlike growth factor I associated with diabetic retinopathy? Diabetes 39, 191–195 (1990).
Dills, D.G., Moss, S.E., Klein, R. & Klein, B.E. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 40, 1725–1730 (1991).
Smith, L.E. et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101–111 (1994).
Hayry, P. et al. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9, 1336–1344 (1995).
Pietrzkowski, Z., Wernicke, D., Porcu, P., Jameson, B.A. & Baserga, R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 52, 6447–6451 (1992).
Kroll, J. & Waltenberger, J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272, 32521–32527 (1997).
Pedram, A., Razandi, M., Hu, R.M. & Levin, E.R. Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J. Biol. Chem. 273, 13966–13972 (1998).
Abedi, H. & Zachary, I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol.Chem. 272, 15442–15451 (1997).
Parenti, A. et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 273, 4220–4226 (1998).
Seger, R. & Krebs, E.G. The MAPK signaling cascade. Faseb. J. 9, 726–735 (1995).
Pedram, A., Razandi, M., Hu, R.M. & Levin, E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J. Biol. Chem. 272, 17097–17103 (1997).
Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. & Saltiel, A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489–27494 (1995).
Baserga, R., Hongo, A., Rubini, M., Prisco, M. & Valentinis, B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1332, F105–126 (1997).
King, G.L., Goodman, A.D., Buzney, S., Moses, A. & Kahn, C.R. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 75, 1028–1036 (1985).
Grant, M.B., Caballero, S. & Millard, W.J. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul. Pept. 48, 267–278 (1993).
Graves, J.D., Campbell, J.S. & Krebs, E.G. Protein serine/threonine kinases of the MAPK cascade. Ann. NY Acad. Sci. 766, 320–343 (1995).
Klemke, R.L. et al. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 137, 481–492 (1997).
Punglia, R.S. et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46, 1619–1626 (1997).
The diabetes control and complications trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 113, 36–51 (1995).
Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K.F., Sandvik, L. & Aagenaes, O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br. Med. J. (Clin. Res. Ed.) 290, 811–815 (1985).
Chantelau, E. & Kohner, E.M. Why some cases of retinopathy worsen when diabetic control improves. Br. Med. J. 315, 1105–1106 (1997).
Hanssen, K.F., Dahl-Jorgensen, K. & Brinchmann-Hansen, O. The influence of strict control on diabetic complications. Acta Endocrinol. Suppl. (Copenh) 272, 57–60 (1985).
Diabetes control and complications trial research group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology 102, 647–661 (1995).
Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).
Moskalets, E., Galstyan, G., Starostina, E., Antsiferov, M. & Chantelau, E. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J. Diabetes Complications 8, 45–50 (1994).
Chantelau, E., Eggert, H., Seppel, T., Schonau, E. & Althaus, C. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome. Br. J. Ophthalmol. 81, 169–170 (1997).
Hammes, H.P., Lin, J., Bretzel, R.G., Brownlee, M. & Breier, G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47, 401–406 (1998).
Holly, J.M., Amiel, S.A., Sandhu, R.R., Rees, L.H. & Wass, J.A. The role of growth hormone in diabetes mellitus. J. Endocrinol. 118, 353–364 (1988).
D'Amato, R., Wesolowski, E. & Smith, L.E. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc. Res. 46, 135–142 (1993).
Capetandes, A. & Gerritsen, M.E. Simplified methods for consistent and selective culture of bovine retinal endothelial cells and pericytes. Invest. Ophthalmol. Vis. Sci. 31, 1738–1744 (1990).
Bischoff, J., Brasel, C., Kraling, B. & Vranovska, K. E-selectin is upregulated in proliferating endothelial cells in vitro. Microcirculation 4, 279–287 (1997).
Zhang, B., Tavare, J.M., Ellis, L. & Roth, R.A. The regulatory role of known tyrosine autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids. J. Biol. Chem. 266, 990–996 (1991).
We thank R. Sullivan for assistance. This work was supported in part by grants from the V. Kann Rasmussen Foundation and the National Eye Institute (EY08670) to L.E.H.S.
About this article
Cite this article
Smith, L., Shen, W., Perruzzi, C. et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5, 1390–1395 (1999). https://doi.org/10.1038/70963
Retinopathy of prematurity: Incidence and perinatal risk factors in a tertiary hospital in Saudi Arabia
Journal of Clinical Neonatology (2021)
Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020)
Zeitschrift für Geburtshilfe und Neonatologie (2021)
Journal of Clinical Medicine (2021)
Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions
Exploration of Medicine (2020)
Medical Journal Armed Forces India (2020)